- RSV (Respiratory Syncytial Virus)
- Vaccine Recommendations for Adults
How do IDSA’s September 2026 RSV recommendations differ from CDC’s current clinical considerations?
The Infectious Diseases Society of America (IDSA) recommends RSV vaccination for immunocompromised adults beginning at age 18. IDSA’s guidance document also expressed support for case-by-case consideration of vaccination of immunocompromised children younger than age 18 years; however, use in nonpregnant people younger than 18 is not an FDA-approved indication, nor is it recommended by the American Academy of Pediatrics (AAP). In contrast, CDC’s risk-based adult recommendation begins at age 50, with routine vaccination of all adults age 75 and older.
IDSA generally recommends one dose, consistent with the FDA and other recommending bodies. IDSA guidance allows for a treating clinician to consider additional doses for an immunocompromised patient on an individual basis, such as when vaccination occurred before optimal immune recovery. CDC and other medical societies do not currently recommend off-label routine revaccination. IDSA provides specific recommended considerations for coordinating timing of vaccination with transplantation, chemotherapy, B-cell-depleting treatment, and when to act before or during periods of elevated RSV activity in the patient’s community. See www.idsociety.org/practice-guideline/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/.


